Loading...
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.
Shitara, K Özgüroğlu, M Bang, Y Bartolomeo, M Mandalà, M Ryu, M Fornaro, L Olesiński, T Caglevic, C Chung, H
Shitara, K
Özgüroğlu, M
Bang, Y
Bartolomeo, M
Mandalà, M
Ryu, M
Fornaro, L
Olesiński, T
Caglevic, C
Chung, H
Citations
Altmetric:
Abstract
Patients with advanced gastric or gastro-oesophageal junction cancer that progresses on chemotherapy have poor outcomes. We compared pembrolizumab with paclitaxel in patients with advanced gastric or gastro-oesophageal junction cancer that progressed on first-line chemotherapy with a platinum and fluoropyrimidine.
Description
Date
2018-06-04
Publisher
Collections
Keywords
Type
Article
Citation
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. 2018, Lancet